Your Source for B12
Recent trials show that overweight or obese patients saw a 14.9% reduction in body weight after taking once-weekly semaglutide 2.4 mg for 68 weeks, compared to a 2.4% reduction in body weight for the control [24]
On August 1, 2025, the JPML reported there are 2,190 cases pending in MDL -3094 IN RE: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation
[12] This reinforces that NAD+ therapy, when administered in a controlled medical setting, has a favorable safety profile
I usually suggest treatments every four to six weeks for at least six months sometimes longer. At home, red-light therapy can provide additional support
Epigenetic clocks are well validated as research tools and have consistently been shown to predict how many healthy years people are likely to live, as well as their risk of chronic disease, disability and death